title: Endothelium-derived prostanoids reduce 5-hydroxytryptamine-induced contraction in the human uterine artery.
abstract: The contribution of endothelium-linked mechanisms to the contraction induced by 5-hydroxytryptamine (5-HT) was investigated in the isolated human uterine artery. 5-HT contracted the uterine artery concentration-dependently. Removal of the endothelium or treatment with the cyclooxygenase inhibitor indomethacin potentiated the contractile response to 5-HT. The nitric oxide synthase inhibitor L-N(G)-monomethyl-arginine (L-NMMA) did not influence the contraction induced by 5-HT. Indomethacin did not affect the response to 5-HT in endothelium-denuded vessels. The 5-HT1 receptor agonist 5-carboxyamidotryptamine (5-CT) did not relax precontracted arteries. Removal of the endothelium did not change the response to 5-HT in the presence of the 5-HT(1B/D) receptor antagonist GR127935 and the 5-HT1A and 5-HT1B receptor antagonist -pindolol. The 5-HT1B receptor antagonist SB224289 did not affect the contraction induced by 5-HT. The results indicate that the 5-HT-induced contraction in the human uterine artery is accompanied by the release of an endothelium-derived relaxing factor (EDRF). This EDRF seems to be a prostanoid, probably prostacyclin (PGI2). The endothelium-linked mechanism seems to be mediated via a 5-HT1 receptor, but it is not possible to further classify the receptor subtype by the information obtained in this study.
authors.affiliation: Department of Obstetrics and Gynaecology, University Hospital, Malmö, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Karlsson
authors.forename: G
authors.initials: G
authors.lastname: Bodelsson
authors.forename: M
authors.initials: M
authors.lastname: Bodelsson
authors.forename: M
authors.initials: M
authors.lastname: Stjernquist
mesh_terms: D000328:Adult; D000368:Aged; D001158:Arteries; D016861:Cyclooxygenase Inhibitors; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000502:physiology; D004791:Enzyme Inhibitors; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011453:Prostaglandins / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000502:physiology; D012701:Serotonin / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D014599:Uterus / Q000098:blood supply*; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D011453:Prostaglandins; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D019323:omega-N-Methylarginine; D012701:Serotonin; D019001:Nitric Oxide Synthase; D007213:Indomethacin